Tesamorelin
BRANDS Egrifta
Last reviewed 2026-10-30
Our read Opinion
A narrowly indicated approved medicine, not a general anti-aging treatment. WADA 2026 S2.2.4 prohibits growth hormone-releasing factors, including tesamorelin.
- Type
- FDA-approved
- Regulatory status
- FDA-approved (Egrifta formulations)
- Compounding status
- Approved product (not applicable)
- FDA-approved indications
- Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management.
- Evidence level
- Human RCTs (approved use)
- Routes studied
- Injection
- WADA
- Prohibited
- Developer
- Theratechnologies
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Reported to reduce visceral fat in its approved population
Growth hormone-releasing hormone analogue that stimulates pituitary growth hormone secretion and increases IGF-1.
FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. The label explicitly excludes general weight-loss management and states that long-term cardiovascular safety is not established.
Statuses change; check the linked primary source.
Momentum Opinion
Steady
0 news items in last 30 days
Evidence for HIV-associated lipodystrophy should not be repackaged as evidence for routine fat loss or rejuvenation. Its endocrine effects and sport prohibition deserve prominent disclosure.
No news yet for this peptide.
Visceral (belly) fat reduction plus a broader GH boost.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.